---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-055809"
form_type: "8-K/A"
ticker: "ABVC"
cik: "0001173313"
company_name: "ABVC BIOPHARMA, INC."
filed_at: "2024-06-25T23:59:59+00:00"
generated_at: "2026-06-01T02:06:32.810869+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# ABVC BioPharma amends licensing deal to allow $3.5M milestone paid incrementally

## Summary
- On June 23, 2024, ABVC and BioLite amended licensing agreements with AiBtl BioPharma for CNS drugs MDD and ADHD.
- The $3.5M second milestone payment can now be paid in increments (e.g., $50,000) at any time instead of lump sum.
- Amendments apply to both the ABVC and BioLite license agreements; no other terms were changed.
- Change suggests potential liquidity strain at licensee AiBtl BioPharma.

## SEC filing metadata
- accession: 0001213900-24-055809
- form_type: 8-K/A
- ticker: ABVC
- cik: 0001173313
- company_name: ABVC BIOPHARMA, INC.
- filed_at: 2024-06-25T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1173313/000121390024055809/0001213900-24-055809-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1173313/000121390024055809/ea0208453-8ka1_abvcbio.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-055809
- JSON: https://secwatch.observer/filing/0001213900-24-055809.json
- Plain text: https://secwatch.observer/filing/0001213900-24-055809.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.